- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01928212
Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis
July 16, 2014 updated by: Yifan Feng
Optical coherence tomography (OCT) is a non-invasive retinal imaging technology that can provide high-resolution cross-sectional images of the peripapillary retinal nerve fiber layer (RNFL) and measure its thickness.
A reduction of the RNFL thickness has been detected in several neurodegenerative diseases, such as multiple sclerosis, CADASIL and Alzheimer's disease.
Different studies have reported RNFL changes also in Parkinson's disease (PD),a common neurodegenerative disease characterized by motor dysfunctions, originally described by James Parkinson in 1817.
PD is characterized by selective dopaminergic neuronal cells loss, which may correlate with RNFL thinning.
Previous studies on this subject, however, reported contradicting results.
Some investigations reported reductions of the RNFL thickness while others did not.
In the present study, in order to determine whether RNFL thickness is reduced in PD patients, we performed a meta-analysis and systematically evaluated RNFL thickness measurements with OCT in a series of PD patients and in the healthy control groups.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- Wenzhou Medical College
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
PD patients and healthy subjects were included and underwent OCT examinations
Description
Inclusion Criteria:
- case-control studies;
- patients with PD were compared with healthy controls;
- all subjects underwent RNFL thickness measurement by OCT;
- studies should provide the data of peripapillary RNFL thickness;
- sample size ≥10 in each group.
Exclusion Criteria:
- authors did not make RNFL measurements;
- study without healthy control group;
- the outcome values can not be used for meta-analysis;
- duplicated articles.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
healthy control
Sex- and agematched healthy subjects
|
|
|
Parkinson group
Patients with Parkinson's disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Retinal Nerve Fiber Layer Thickness
Time Frame: Baseline
|
Retinal nerve fiber layer thickness included average thickness (360° measurement), temporal quadrant thickness (316-45°), superior quadrant thickness (46-135°), nasal quadrant thickness (136-225°) and inferior quadrant thickness (226-315°)was measured by OCT.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yifan Feng, PhD, Wenzhou Medical University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
January 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
August 20, 2013
First Submitted That Met QC Criteria
August 22, 2013
First Posted (Estimate)
August 23, 2013
Study Record Updates
Last Update Posted (Estimate)
July 18, 2014
Last Update Submitted That Met QC Criteria
July 16, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FYF20130820
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
Bezmialem Vakif UniversityRecruitingParkinson Disease | Parkinson | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseTurkey (Türkiye)
-
CND Life SciencesDigestive Disease Associates of CTRecruitingParkinson Disease | Parkinson | PARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Neuron23 Inc.Roche Diagnostic Ltd.; Qiagen Manchester LimitedRecruitingParkinson Disease | Parkinson | Idiopathic Parkinson Disease | Parkinson Disease, Idiopathic | Early Parkinson Disease (Early PD)United States, Spain, Israel, Poland, Italy, United Kingdom
-
San Francisco Neurology and Sleep CenterRecruitingPARKINSON DISEASE (Disorder) | Parkinson s DiseaseUnited States
-
Haukeland University HospitalUniversity of Bergen; SPARK NSRecruitingParkinson Disease (PD) | Parkinson s DiseaseNorway
-
Bezmialem Vakif UniversityIstanbul University - CerrahpasaNot yet recruitingParkinson Disease | PARKINSON DISEASE (Disorder) | Parkinson Disease (PD), Postural Balance
-
CND Life SciencesOregon Health and Science UniversityRecruitingParkinson Disease | Parkinson | Parkinson's Disease and Parkinsonism | PARKINSON DISEASE (Disorder)United States
-
Università degli Studi dell'InsubriaUniversidade Nova de Lisboa; Associazione Parkinson Insubria (AsPI), Section... and other collaboratorsRecruitingParkinson Disease | Parkinson | Parkinson Disease, Idiopathic | PARKINSON DISEASE (Disorder)Italy
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
Duke UniversityMedical University of South Carolina; Massachusetts General Hospital; Mayo Clinic and other collaboratorsNot yet recruitingGut Microbiota | Gut Microbiome | Parkinson Disease (PD) | PARKINSON DISEASE (Disorder) | Prodromal Parkinsons DiseaseUnited States
Clinical Trials on Optical coherence tomography
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedCerebral AneurysmUnited States
-
Samsung Medical CenterCompleted
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedTransitional Cell Carcinoma of Urinary TractNetherlands
-
Kasr El Aini HospitalCompletedTractional Retinal Detachment | Diabetic Vitreous HemorrhageEgypt
-
Khon Kaen UniversityRecruitingRetinal Vascular | Twin Pregnancy, Antepartum Condition or Complication | Choroidal EffusionThailand
-
Khon Kaen UniversityNot yet recruiting
-
The Cleveland ClinicRecruitingRefractive Errors | Keratoconus | Cornea; EctasiaUnited States
-
Centre Hospitalier Universitaire, AmiensCompletedAlzheimer Disease | Lewy Body Disease | Retina | Optical Coherence Tomography | Cortical Atrophy | Optical Coherence Tomography Angiography | Retinal Thickening | Retinal Nerve Fibres LayerFrance
-
University of NebraskaRecruitingRefractive Errors | Myopia | Optical Coherence TomographyUnited States
-
Nitin VaswaniCompletedCorneal Disease | Corneal Transplant Failure | Endothelial Corneal Dystrophy | Corneal Transplant RejectionUnited States